Navigating Treatment Options in Low-Risk Myelodysplastic Syndromes
This video explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes.
With advances in the understanding of myelodysplastic syndromes (MDS), both in the pathogenesis and biology of the disease, and with newer treatments and methods of supportive care, survival of patients with MDS has markedly improved.
In this video, Valeria Santini, MD, of the University of Florence in Italy, explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes.
Santini also discusses treatment decisions based on molecular alterations and when experimental therapies might be most appropriate.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT
June 2nd 2025Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.
